Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
By:
Lowey Dannenberg, P.C. via
GlobeNewswire
May 17, 2024 at 11:47 AM EDT
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) for violations of the federal securities laws on behalf of investors who purchased or acquired Altimmune common stock between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”). On May 6, 2024, a complaint was filed against the Company and certain of its current officers alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, Defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. When investors learned the truth, Altimmune’s common stock declined precipitously, injuring investors. If you suffered a loss of more than $100,000 in Altimmune’s securities, and wish to participate, or learn more, please contact our attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. (vcappucci@lowey.com). Any investor who wishes to serve as Lead Plaintiff must act before July 5, 2024. About Lowey Dannenberg Contact: SOURCE: Lowey Dannenberg P.C.
More NewsView More
The Contrarian Case for MSTR Amid MSCI Delisting Debacle ↗
Today 17:46 EST
Via MarketBeat
Tickers
MSTR
Worried About Mag 7 Concentration Risk? This ETF Could Help ↗
Today 16:16 EST
Via MarketBeat
Here's Who Wins If Trump's 50-Year Mortgages Come to Market ↗
Today 13:00 EST
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|

